Effektivnost' i bezopasnost' primeneniya dvukhfaznogo analoga insulina NovoMiks 30 pri sakharnom diabete 2 tipa: ot klinicheskikh issledovaniy do real'noy praktiki


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Biphasic (or premix) formulations of insulin contain a fixed ratio of short- (or ultra-short-) and intermediate-action insulin. Currently, this group includes several products of premixed insulin both human insulin as well as insulin analogues. NovoMix 30 is used in the world clinical practice for over 10 years and remains one of the most studied preparation of insulin; efficacy and safety of NovoMix 30 are confirmed by numerous randomized clinical trials and large observational programs. Comparative studies of NovoMix 30 and biphasic human insulins, as well as analogues insulins with different ratios of short-acting and long-acting fractions were performed. The studies' results demonstrated a high level of efficiency and safety, especially with regard to the risk of hypoglycemia and the effect on body weight. NovoMix 30 is suitable for both initiation and for the intensification of insulin therapy, because enables the use of one drug in a single insulin delivery system, with individual adjusting doses and increase the number of injections, if needed. Furthermore, the use of a simple titration algorithm enhances adherence of patients to a regimen of therapy recommended by a physician.

Full Text

Restricted Access

About the authors

E. V Surkova

Email: elenasurkova@mail.ru

References

  1. Liebl A., Prusty V., Valensy P., et al. Ten years of experience with biphasic insulin aspart 30. From drug development to the latest clinical findings. Drugs. 2012; 72(11): 1495-520.
  2. Суркова Е.В. Десять лет применения в мире и России инсулина НовоМикс 30. Сахарный диабет. 2013; (4): 101-7.
  3. Weyer C., Heise T., Heinemann L. Insulin aspart in 30/70 premixed formulation: pharmacodynamic propertis of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997; 20: 1612-14.
  4. Chen J.W., Lauritzen T., Bojesen A., Christiansen J.S. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes. Metab. 2006; 8: 682-89.
  5. McSorley K.M., Bell P.M., Jacobsen L.V., et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind crossover study in adults with type 2 diabetes mellitus. Clin. Ther. 2002; 24: 530-39.
  6. McNally P.G., Dean J.D., Morris D., et al. Used continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007; 30: 1044-48.
  7. Rizvi A.A., Lightelm R.J. The use of premixed insulin analogs in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin. 2007; 2: 68-79.
  8. Boehm B.O., Home P.D., Kamp B.N.M., et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet. Med. 2002; 19: 393-99.
  9. Boehm B.O., Vaz J.A., Bronsted L. Home P.D. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur. J. Inter. Med. 2004; 15: 496-502.
  10. Heise T., Heinemann L., Hovelmann U., et al. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy. Diabetes Care. 2009; 32: 1431-33.
  11. Jacobsen L.V., Sogaard B., Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol. 2000; 56: 399-403.
  12. Ligthelm R.J., Mouritzen U., Lynggaard H., Landin-Olsson M., Fox C., le Devehat C., Romero E., Liebl A. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006; 114(9): 511-519
  13. Niskanen L., Jensen L.E., Rastam J., et al. Randomized, multinational, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin. Ther. 2004; 26(4): 531-40.
  14. Hermansen K., Colombo M., Storgaard H., et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002; 25: 883-88.
  15. Farcasiu E., Ivanyi T., Mozejko-Pastewka B., et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clin. Ther. 2011; 33: 16782-93.
  16. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or twice-daily dosingwith byphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes. Metab. 2006; 8: 58-66.
  17. Lightelm R.J. Self-titration of biphasic insulin aspart 3070 improves glycemic control and allows easy intensification in Dutch clinical practice. Prim. Care Diabetes. 2009; 3: 97-102.
  18. Shestakova M., Sharma S.K., Almustafa M., et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr. Med. Res. Opin. 2007; 23(12): 3209-14.
  19. Khutsoane D., Sharma S.K., Almustafa M., et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes. Metab. 2008; 10: 212-22.
  20. Sharma S.K., Al-Mustafa M., Oh S.J., et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Res. Opin. 2008; 24(3): 645-52.
  21. Jang H.C., Guler S., Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. int. J. Clin. Pract. 2008; 62(7): 1013-18.
  22. Guler S., Sharma S.K., Almustafa M., et al. improved Glycaemic Control with Biphasic insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Arch. Drug inf. 2009; 2(2): 23-33.
  23. Shah S., Benroubi M., Borzi V., et al. on behalf of the IMPROVE™ Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study. int. J. Clin. Pract. 2009; 63(4): 574-82.
  24. Gumprecht J., Benroubi M., Borzi V., et al. on behalf of the iMPROVE Study Group Expert Panel. intensification to biphasic insulin aspart 30/70 (BiAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the iMPROVE observational study. int. J. Clin. Pract. 2009; 63(6): 966-72.
  25. Home Ph., El Naggar N., Khamseh M., et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res. & Clin. Pract. 2011; (94): 352-63.
  26. Shah S., Zilov A., Malek R., et al. improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Res. & Clin. Pract. 2011; 94(3): 364-70.
  27. El Naggar N.K., Soewondo P., Khamseh M.E., et al. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study. Diabetes Res. & Clin. Pract. 2012; 98(3): 408-13.
  28. Haddad J., Khoshniatnikoo M., Benabbas Y., et al. Safety and effectiveness of switching from a basal-only to biphasic insulin aspart 30 insulin regimen. Diabetes Ther 2013; 4: 309-19.
  29. Khamseh M.E., Haddad J., Yang W., et al. Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: A1chieve sub-analysis. Diabetes Ther. 2013; 4: 347-61.
  30. Shah S., Yang W., Hasan M.I., et al. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: Results from a regional comparative multinational observational study (A1chieve). Diabetes Technol. & Ther. 2013; 15(11): 954-63.
  31. Hajjaji i., Shah S., Li Y., et al. Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with basal insulin: findings from the multinational, non-interventional A1chieve study. Diabetes The. 2014; 5(1): 113-26.
  32. Шестакова М.В. Наблюдательная программа iMPROVETM - безопасность и эффективность двухфазного инсулина аспарт 30 в рутинной клинической практике. Обзор исходных характеристик Российской когорты пациентов. Сахарный диабет. 2009; 4: 103-08.
  33. Шестакова М.В. Терапия двухфазным инсулином аспарт 30/70 (НовоМикс 30) улучшает гликемический контроль у пациентов с сахарным диабетом 2 типа: данные российской когорты пациентов наблюдательной программы IMPROVETM -программы по изучению безопасности и эффективности двухфазного инсулина аспарт 30 в рутинной клинической практике. Сахарный диабет. 2010; 1: 3-10.
  34. Шестакова М.В. Эффективность и безопасность терапии аналогами инсулина у ранее не получавших инсулин пациентов с сахарным диабетом 2 типа в повседневной клинической практике: результаты многоцентрового наблюдательного 52-недельного исследования A1chive. Сахарный диабет. 2012; 4: 113-19.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies